I wouldn't know what will happen in the next few 3-6-12 months, and I would be confident that no-one else on this forum would either.
What I am sure of is that we have some of the best IP in play with long patent timelines.
We have also gathered data in many patients that tell us much more about the mechanism of action that our potential treatments have, which patients it works very well in and the duration of holding cancer at bay.
All the latest news is about CAR-Ts and their effectiveness in eliminating blood cancers, many are now working toward how to use multiple treatments to fight solid tumours, 90% of the market.
We know our IP is unique and cutting edge and we have a team of scientists that have helped to develop several FDA approved drugs, they know what is required and they would be fully aware of the competition.
While I feel for many shareholders that are deep in the red, on paper, I just cannot comprehend why you would sell when on the cusp of breaking news, as least wait for the news and the potential bump up in shareprice, and then get out.
This has to be the bottom as the IP in vaxinia alone would be worth multiples of the current shareprice.
Best wishes to all holders over the summer break and hopefully the New Year brings us go9d new on the data front.
DYOR opinion only
IMU Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)